GW
SNOA icon

GW & Wade’s Sonoma Pharmaceuticals SNOA Stock Holding History

GW & Wade’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-61
Closed -$10K – 241
2019
Q1 		$10K Hold
61
– – ﹤0.01% 229
2018
Q4 		$8K Hold
61
– – ﹤0.01% 219
2018
Q3 		$16K Hold
61
– – ﹤0.01% 239
2018
Q2 		$27K Sell
61
-1
-2% -$652 ﹤0.01% 240
2018
Q1 		$41K Buy
62
+1
+2% +$822 ﹤0.01% 231
2017
Q4 		$60K Buy
+61
New +$52.2K 0.01% 214
2016
Q2 		– Sell
-50
Closed -$43K – 240
2016
Q1 		$43K Hold
50
– – 0.01% 212
2015
Q4 		$52K Hold
50
– – 0.01% 215
2015
Q3 		$58K Buy
50
+33
+194% +$39.1K 0.01% 217
2015
Q2 		$21K Hold
17
– – ﹤0.01% 230
2015
Q1 		$13K Buy
+17
New +$14.4K ﹤0.01% 240

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

GW & Wade's SNOA Position: Q2 2019 in Review

GW & Wade sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2019, closing a stake of 61 shares — an estimated $10K sold.

GW & Wade first reported a position in SNOA in Q1 2015 and held it in 11 quarters. The position peaked at $60K in Q4 2017. 13 funds tracked by Wall St. Rank hold SNOA as of Q2 2019.

  • GW & Wade reported no remaining Sonoma Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • GW & Wade sold 61 Sonoma Pharmaceuticals shares in Q2 2019, an estimated $10K.
  • GW & Wade first reported a position in Sonoma Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • GW & Wade's Sonoma Pharmaceuticals position peaked at $60K in Q4 2017.
  • 13 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2019.

Based on GW & Wade's 13F filing for Q2 2019, filed 12 Aug 2019.